Glioblastoma | Norton Healthcare

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Indication: Glioblastoma

EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study of Optune® (TTFields, 200khz) Concomitant with Radiation Therapy and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Sub-indication: CNS Cancer

Study Type: Device Study

Principal Investigator: Renato LaRocca, M.D.
Norton Brain Tumor Center

Sponsor: Sponsor: NovoCure

Learn more at ClinicalTrials.gov

Email for more information: CNS-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.

As we continue to seek to protect our patients, face masks are required in patient settings such as hospitals, doctors’ offices and medical centers.

Glioblastoma Clinical Trial

Schedule an Appointment